eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
abstract:
Review paper

The potential role of cyclosporine A in cancer treatment: a comprehensive literature review

Adnan Fojnica
1
,
Zehra Gromilic
2
,
Youssef Alaaeldin Ali Mohamed
3
,
Saghir Akhtar
3
,
Semir Vranic
3

  1. Technical University of Munich, Germany
  2. Graz University of Technology, Austria
  3. College of Medicine, Qatar University, Qatar
Contemp Oncol (Pozn) 2024; 28 (4): 271–282
DOI: https://doi.org/10.5114/wo.2024.147009
Online publish date: 2025/01/15
View full text Get citation
 
PlumX metrics:
Cyclosporine A (CsA) is widely used as an immunosuppressant in organ transplantation to improve graft survival and prevent tissue rejection. The impact of CsA on cancer progression is highly complex, influenced by the intricate relationship between immunosuppression and malignancy. While individuals with compromised immune systems, notably organ transplant recipients, face an elevated risk of cancer invasion and progression due to immunosuppressive regimens, CsA’s role in either promoting or inhibiting cancer remains elusive. Divergent outcomes from in vitro and in vivo studies suggest suppression of cancer progression under CsA treatment and complicate the translation of findings to clinical scenarios. Despite promising in vitro and in vivo results, the clinical application of CsA in oncology necessitates careful consideration of its toxicity profile in in vivo models, starting at 50–200 mg/kg/d. The divergence between preclinical and clinical findings highlights the need for further research to elucidate the true nature of CsA’s impact on cancer, providing a foundation for more informed and targeted therapeutic approaches.
keywords:

cyclosporine A, cancer, immunosuppression, cancer treatment
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.